Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Aarti Pharmalabs Limited ( (IN:AARTIPHARM) ) has provided an update.
Aarti Pharmalabs Limited has inaugurated the first phase of its new state-of-the-art manufacturing facility in Atali, Gujarat, marking a significant milestone in its growth strategy. This facility, with a reactor capacity of 440 kL, is expected to serve as a growth engine for the company’s CDMO/CMO business and enhance its intermediates capacity, with future scalability up to 8-10 times. The new site will help the company strengthen its product portfolio and serve large pharmaceutical companies, aligning with its revenue goal of Rs. 1000 crores and commitment to specialized pharmaceutical needs.
More about Aarti Pharmalabs Limited
Aarti Pharmalabs Limited is a prominent Indian pharmaceutical and nutraceutical manufacturer with a global presence, focusing on innovation and sustainability. The company specializes in comprehensive CDMO/CMO services for small molecule drug substances, catering to clinical and commercial phase projects for innovator pharma companies. It offers dedicated facilities for HPAPIs, corticosteroids, cytotoxic, and oncology products, and is a leading producer of generic APIs, Intermediates, and Xanthine derivatives.
Average Trading Volume: 19,172
Technical Sentiment Signal: Buy
Current Market Cap: 77.66B INR
See more data about AARTIPHARM stock on TipRanks’ Stock Analysis page.